



This poster summarizes the RWE working group activities that started in April 2023. It includes our activities and achievements pertaining to efforts taken for development of industry guidance, approaches towards submission of real-world data and for fit for purpose assessment of real-world data.

Community Forums 2023/2024

July '23: Designing Your RWD Study: Is Your Data Fit for Purpose

- Jonathan Assayag (Pfizer), Elizabeth Merrall (JnJ) & Andy Richardson (Zenetar)

October '23: Experiences with Adapting RWD to CDISC Submission Standards

- Lauren Green (Amgen), Christine Rossin & Sandra VanPelt Nguyen (Pfizer) & Jeff Abolafia (Pinnacle 21)

January '24: RWD Quality Challenges – Different Perspectives


- Cheryl Grandinetti (FDA) & Kris Wenzel (MMS)

April '24: Meet the Real-World Data Provider


- Michele Arnoe (IQVIA), Jeff Brown (TriNetX) & Ben Forred (Sanford Health)

July '24: Understanding the Journey of Real-World Data


Best Data Practices for Rare Disease
Patient Foundations and Researchers



Quality and reusability of RWD



RWD Guideline for Programming Analyses and Processes



Estimands for Real-World Data and Real-World Evidence

